

# Sarah-Jane Dawson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6355800/publications.pdf>

Version: 2024-02-01

51  
papers

10,974  
citations

126858

33  
h-index

182361

51  
g-index

54  
all docs

54  
docs citations

54  
times ranked

18051  
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 1199-1209.	13.9	1,884
2	Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. <i>Nature</i> , 2013, 497, 108-112.	13.7	1,443
3	The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. <i>Nature Communications</i> , 2016, 7, 11479.	5.8	1,221
4	Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA. <i>Science Translational Medicine</i> , 2012, 4, 136ra68.	5.8	1,086
5	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 406-414.	5.1	703
6	BET inhibitor resistance emerges from leukaemia stem cells. <i>Nature</i> , 2015, 525, 538-542.	13.7	441
7	Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. <i>Nature Communications</i> , 2015, 6, 8760.	5.8	409
8	An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. <i>Cancer Cell</i> , 2019, 36, 385-401.e8.	7.7	359
9	Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 1211-1223.	13.9	343
10	Non-genetic mechanisms of therapeutic resistance in cancer. <i>Nature Reviews Cancer</i> , 2020, 20, 743-756.	12.8	290
11	Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. <i>Science</i> , 2020, 368, 387-394.	6.0	274
12	A new genome-driven integrated classification of breast cancer and its implications. <i>EMBO Journal</i> , 2013, 32, 617-628.	3.5	267
13	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 134, 39-45.	2.0	200
14	Multi-omic machine learning predictor of breast cancer therapy response. <i>Nature</i> , 2022, 601, 623-629.	13.7	187
15	Reversion of <i>BRCA1/2</i> Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1274-1280.	0.8	157
16	Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. <i>Nature Medicine</i> , 2019, 25, 119-129.	15.2	147
17	Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia. <i>Nature Communications</i> , 2019, 10, 2723.	5.8	126
18	Click chemistry enables preclinical evaluation of targeted epigenetic therapies. <i>Science</i> , 2017, 356, 1397-1401.	6.0	120

#	ARTICLE	IF	CITATIONS
19	The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program <i>PLoS Medicine</i> , 2016, 13, e1002204.	3.9	119
20	HBO1 is required for the maintenance of leukaemia stem cells. <i>Nature</i> , 2020, 577, 266-270.	13.7	105
21	A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2019, 9, 354-369.	7.7	104
22	Functional interdependence of BRD4 and DOT1L in MLL leukemia. <i>Nature Structural and Molecular Biology</i> , 2016, 23, 673-681.	3.6	92
23	The value of cell-free DNA for molecular pathology. <i>Journal of Pathology</i> , 2018, 244, 616-627.	2.1	91
24	Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 883-892.	1.2	81
25	Non-genetic determinants of malignant clonal fitness at single-cell resolution. <i>Nature</i> , 2022, 601, 125-131.	13.7	71
26	Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia. <i>Nature Communications</i> , 2017, 8, 14756.	5.8	70
27	A community-based model of rapid autopsy in end-stage cancer patients. <i>Nature Biotechnology</i> , 2016, 34, 1010-1014.	9.4	66
28	HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults. <i>Nature Medicine</i> , 2021, 27, 1006-1011.	15.2	62
29	Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes. <i>Blood</i> , 2017, 129, 1685-1690.	0.6	53
30	Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2017, 1, 1-14.	1.5	51
31	Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. <i>Anti-Cancer Drugs</i> , 2008, 19, 547-552.	0.7	48
32	Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. <i>Nature Communications</i> , 2021, 12, 1434.	5.8	46
33	Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing. <i>Blood</i> , 2020, 136, 572-584.	0.6	44
34	Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late. <i>Diagnostics</i> , 2021, 11, 103.	1.3	33
35	Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study. <i>Blood</i> , 2019, 134, 756-756.	0.6	24
36	Detection of cell-free microbial DNA using a contaminant-controlled analysis framework. <i>Genome Biology</i> , 2021, 22, 187.	3.8	22

#	ARTICLE	IF	CITATIONS
37	Cancer Risk Management Practices of Noncarriers Within BRCA1/2 Mutation-Positive Families in the Kathleen Cunningham Foundation Consortium for Research Into Familial Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 225-232.	0.8	19
38	Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study. <i>PLoS Medicine</i> , 2020, 17, e1003363.	3.9	18
39	Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death. <i>Cancer Discovery</i> , 2022, 12, 774-791.	7.7	18
40	Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study. <i>Cancer Discovery</i> , 2022, 12, 2058-2073.	7.7	16
41	Liquid biopsies for residual disease and recurrence. <i>Med</i> , 2021, 2, 1292-1313.	2.2	15
42	Wet or Dry? Do Liquid Biopsy Techniques Compete with or Complement PET for Disease Monitoring in Oncology?. <i>Journal of Nuclear Medicine</i> , 2017, 58, 869-870.	2.8	8
43	Characterizing the Cancer Genome in Blood. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a026880.	2.9	7
44	Combining liquid biopsies and PET-CT for early cancer detection. <i>Nature Medicine</i> , 2020, 26, 1010-1011.	15.2	7
45	Hypocalcemia associated with bone metastases in a patient with salivary-gland carcinoma. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 104-107.	4.3	5
46	Blood Worth Bottling: Circulating Tumor DNA as a Cancer Biomarker. <i>Cancer Research</i> , 2016, 76, 5590-5591.	0.4	5
47	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. <i>Oncologist</i> , 2022, 27, e561-e570.	1.9	5
48	Large B-cell lymphoma: is the future written in the blood?. <i>Lancet Oncology</i> , The, 2015, 16, 481-483.	5.1	3
49	Plasma and tumor genomic correlates of response to BYL719 in PI3KCA mutated metastatic ER-positive breast cancer (ER+/HER2- BC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1055-1055.	0.8	3
50	Clinical validation and implementation of droplet digital PCR for the detection of BRAF mutations from cell-free DNA. <i>Pathology</i> , 2022, 54, 772-778.	0.3	2
51	Custom workflows to improve joint variant calling from multiple related tumour samples: FreeBayesSomatic and Strelka2Pass. <i>Bioinformatics</i> , 2021, , .	1.8	0